Jeffrey L. Cummings
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jeffrey L. Cummings has a total of 287 co-authors. Here are the top co-authors by number of shared publications:
Harry V. Vinters
3 shared publicationsDonna Masterman
1, 5Department of Psychiatry and Biobehavioral Science, UCLA School of Medicine
2 shared publications- John Matthew Ringman
Department of Neurology, Keck School of Medicine at USC, Los Angeles, CA, USA
2 shared publications Justine Garakian
2 shared publicationsLynn Fairbanks
2 shared publicationsA. Jon Stoessl
1 shared publication
Latest Publications
- 5 September 2015
- Published by Cambridge University Press (CUP)
- p. 3-5
Introduction to Section 1
Now available in paperback, this updated new edition summarizes the latest developments in cognitive neuroscience related to rehabilitation, reviews the principles of successful interventions and synthesizes new findings about the rehabilitation of cognitive changes in a variety of populations. With greatly expanded sections on treatment and the role of imaging, it provides a comprehensive reference for those interested in the science, as well as including the most up-to-date information for the practising clinician. It provides clear and practical guidance on why cognitive rehabilitation may or may not work. How to use imaging methods to evaluate the efficacy of interventions. What personal and external factors impact rehabilitation success. How biological and psychopharmacological changes can be understood and treated. How to treat different disorders of language and memory, and where the field is going in research and clinical application.
- 5 September 2015
- Published by Cambridge University Press (CUP)
- p. 3-5
Introduction to Section 1
Now available in paperback, this updated new edition summarizes the latest developments in cognitive neuroscience related to rehabilitation, reviews the principles of successful interventions and synthesizes new findings about the rehabilitation of cognitive changes in a variety of populations. With greatly expanded sections on treatment and the role of imaging, it provides a comprehensive reference for those interested in the science, as well as including the most up-to-date information for the practising clinician. It provides clear and practical guidance on why cognitive rehabilitation may or may not work. How to use imaging methods to evaluate the efficacy of interventions. What personal and external factors impact rehabilitation success. How biological and psychopharmacological changes can be understood and treated. How to treat different disorders of language and memory, and where the field is going in research and clinical application.
- 1 January 2012
- Published by Elsevier
Contributors
- 1 December 2010
- Published by Oxford University Press (OUP)
- p. 197-211
Frontotemporal Dementia and Related Syndromes
- 1 December 2010
- Published by Oxford University Press (OUP)
- p. 197-211
Frontotemporal Dementia and Related Syndromes
- Open Access
- 1 January 2007
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Psiquiatria
- Vol. 56 (2) , 81-82
The neuropsychiatric disturbances in demential disorders or behavioral and psychological symptoms of dementia
- 1 January 2007
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Psiquiatria
- Vol. 56 (2) , 81-82
Open AccessThe neuropsychiatric disturbances in demential disorders or behavioral and psychological symptoms of dementia
- 1 November 2004
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 1 (4) , 323-328
Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Effective drug development depends on understanding and optimizing results from controlled clinical trials. A recent double-blind, randomized, controlled trial of the treatment of agitation in patients with Alzheimer's disease (AD) found no difference among the four arms of the study: haloperidol, trazodone, behavioral therapy, placebo. The current analysis was undertaken to further investigate the issues bearing on this outcome and to identify better means of detecting psychotropic effects in trials involving patients with AD. This was post hoc analysis of a clinical trial data set. Patients in the placebo group were divided into responders (25% reduction in symptoms), worseners (25% worsening in baseline agitation scores), and those without a change in symptoms. Analysis of the trial outcomes demonstrated that the reduction observed in the placebo group was of the same magnitude as predicted by regression to the mean. Patients exhibiting greater improvement had more severe baseline behavioral disturbances. The relatively modest severity of agitation and the low medication doses achieved in the study may have further contributed to the failure to distinguish among treatment groups. Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials.
- 1 November 2004
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 1 (4) , 323-328
Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Effective drug development depends on understanding and optimizing results from controlled clinical trials. A recent double-blind, randomized, controlled trial of the treatment of agitation in patients with Alzheimer's disease (AD) found no difference among the four arms of the study: haloperidol, trazodone, behavioral therapy, placebo. The current analysis was undertaken to further investigate the issues bearing on this outcome and to identify better means of detecting psychotropic effects in trials involving patients with AD. This was post hoc analysis of a clinical trial data set. Patients in the placebo group were divided into responders (25% reduction in symptoms), worseners (25% worsening in baseline agitation scores), and those without a change in symptoms. Analysis of the trial outcomes demonstrated that the reduction observed in the placebo group was of the same magnitude as predicted by regression to the mean. Patients exhibiting greater improvement had more severe baseline behavioral disturbances. The relatively modest severity of agitation and the low medication doses achieved in the study may have further contributed to the failure to distinguish among treatment groups. Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials.
- Open Access
- 1 August 2004
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 61 (8) , 1249-1253
Association of the Serotonin Transporter and Receptor Gene Polymorphisms in Neuropsychiatric Symptoms in Alzheimer Disease
Serotonin has been associated with various neuropsychiatric symptoms in Alzheimer disease (AD), such as agitation/aggression, depression, or psychosis.1 These noncognitive symptoms, and in particular agitation, constitute a major source of distress for the patient's caregiver and increase the likelihood of nursing home placement.2,3 Recent genetic studies in AD showed associations between several polymorphisms of the serotonin neurotransmitter genes and some neuropsychiatric symptoms. A 102T/C polymorphism in the 5-HT2A receptor (5-HT2AR) gene was associated with visual and auditory hallucinations4 or psychosis5 in patients with AD. The Cys23Ser polymorphism in the 5-HT2C receptor (5-HT2CR) gene was significantly associated with visual hallucinations and hyperphagia in another sample of patients with AD.4 A 44–base pair (bp) insertion (the long form or l form) of the 5-HTT promoter region (5-HTTPR) was reported to be associated with psychosis and aggression.6,7 A variable number tandem repeat (VNTR) polymorphism in intron 2 of the 5-HTT gene was also associated with susceptibility to unipolar or bipolar depression,8 but this association was not found in patients with AD with depression.9 The purpose of this brief study was to examine whether variations in serotonin genes were related to neuropsychiatric symptoms in a sample of patients with AD. Based on the literature, we addressed the following questions: (1) Are 5-HT2AR and 5-HT2CR polymorphisms associated with psychosis (delusions, hallucinations)? (2) Are these polymorphisms related to agitation/aggression? and (3) Are 5-HTTPR and 5-HTTVNTR polymorphisms associated with anxiety, depression, or agitation/aggression in patients with AD?
- 1 August 2004
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 61 (8) , 1249-1253
Open AccessAssociation of the Serotonin Transporter and Receptor Gene Polymorphisms in Neuropsychiatric Symptoms in Alzheimer Disease
Serotonin has been associated with various neuropsychiatric symptoms in Alzheimer disease (AD), such as agitation/aggression, depression, or psychosis.1 These noncognitive symptoms, and in particular agitation, constitute a major source of distress for the patient's caregiver and increase the likelihood of nursing home placement.2,3 Recent genetic studies in AD showed associations between several polymorphisms of the serotonin neurotransmitter genes and some neuropsychiatric symptoms. A 102T/C polymorphism in the 5-HT2A receptor (5-HT2AR) gene was associated with visual and auditory hallucinations4 or psychosis5 in patients with AD. The Cys23Ser polymorphism in the 5-HT2C receptor (5-HT2CR) gene was significantly associated with visual hallucinations and hyperphagia in another sample of patients with AD.4 A 44–base pair (bp) insertion (the long form or l form) of the 5-HTT promoter region (5-HTTPR) was reported to be associated with psychosis and aggression.6,7 A variable number tandem repeat (VNTR) polymorphism in intron 2 of the 5-HTT gene was also associated with susceptibility to unipolar or bipolar depression,8 but this association was not found in patients with AD with depression.9 The purpose of this brief study was to examine whether variations in serotonin genes were related to neuropsychiatric symptoms in a sample of patients with AD. Based on the literature, we addressed the following questions: (1) Are 5-HT2AR and 5-HT2CR polymorphisms associated with psychosis (delusions, hallucinations)? (2) Are these polymorphisms related to agitation/aggression? and (3) Are 5-HTTPR and 5-HTTVNTR polymorphisms associated with anxiety, depression, or agitation/aggression in patients with AD?
- Open Access
- 1 April 2004
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 61 (4) , 556-560
Executive Dysfunction in Alzheimer Disease
Alzheimer disease (AD) affects an estimated 4 million people in the United States and is the leading cause of late-onset dementia worldwide. Its core features include impairments in memory, visuospatial functions, language, executive functions (EFs), and neuropsychiatric symptoms.1 Defined as the ability to abstract, plan, organize, shift set, and adapt current and past knowledge to future behavior, EF occurs in AD, but its prevalence and relationship to other clinical and demographic features of the disease are unknown. Recent studies2-4 suggest that executive dysfunction (EDF) is a common manifestation of AD and occurs in all stages of the illness, although it is more mild than in the frontotemporal lobar degenerations. There also is evidence to support a frontal variant of AD. Johnson et al5 conducted a clinicopathologic study on a sample of 16 patients with AD and found that there was a subset that had early and prominent impairment on tests of EF; other test scores were similar across the groups. Autopsy studies of the frontal variant patients revealed significant increases in the number of neurofibrillary tangles in the frontal cortex compared with patients with more typical AD. Several studies6,7 using standard neuropsychological tests of EF have demonstrated links among EDF and functional decline measured by poor performance on activities of daily living (ADL) scales. Using functional imaging and neuropathologic data, a link has been found between frontal involvement and psychosis in AD8-10 and between agitation and frontal dysfunction, suggesting that EDF might be linked to behavioral disorders.11-16
- 1 April 2004
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 61 (4) , 556-560
Open AccessExecutive Dysfunction in Alzheimer Disease
Alzheimer disease (AD) affects an estimated 4 million people in the United States and is the leading cause of late-onset dementia worldwide. Its core features include impairments in memory, visuospatial functions, language, executive functions (EFs), and neuropsychiatric symptoms.1 Defined as the ability to abstract, plan, organize, shift set, and adapt current and past knowledge to future behavior, EF occurs in AD, but its prevalence and relationship to other clinical and demographic features of the disease are unknown. Recent studies2-4 suggest that executive dysfunction (EDF) is a common manifestation of AD and occurs in all stages of the illness, although it is more mild than in the frontotemporal lobar degenerations. There also is evidence to support a frontal variant of AD. Johnson et al5 conducted a clinicopathologic study on a sample of 16 patients with AD and found that there was a subset that had early and prominent impairment on tests of EF; other test scores were similar across the groups. Autopsy studies of the frontal variant patients revealed significant increases in the number of neurofibrillary tangles in the frontal cortex compared with patients with more typical AD. Several studies6,7 using standard neuropsychological tests of EF have demonstrated links among EDF and functional decline measured by poor performance on activities of daily living (ADL) scales. Using functional imaging and neuropathologic data, a link has been found between frontal involvement and psychosis in AD8-10 and between agitation and frontal dysfunction, suggesting that EDF might be linked to behavioral disorders.11-16
- 1 March 2004
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 161 (3) , 532-538
Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer’s Disease
Alzheimer's disease pathology includes both histologic changes and neurotransmitter deficits. The cholinergic deficit contributes to both cognitive and behavioral disturbances, and cholinesterase inhibitors may improve behavior in Alzheimer's disease patients. This analysis was conducted to assess the impact of galantamine, a cholinesterase inhibitor with nicotinic-receptor-modulating properties, on the pattern and evolution of behavioral disturbances in patients with Alzheimer's disease and on caregiver distress related to patients' behavior. Data from 978 patients with mild to moderate Alzheimer's disease who were randomly assigned to placebo or galantamine (8, 16, or 24 mg/day) were analyzed. Behavioral changes were assessed with the Neuropsychiatric Inventory, and alterations in caregiver distress were measured by the Neuropsychiatric Inventory distress scale. Data collected at baseline and 12 and 21 weeks postbaseline were analyzed. Neuropsychiatric Inventory scores worsened with placebo, whereas patients treated with 16 or 24 mg/day of galantamine had no change in total Neuropsychiatric Inventory scores. Treated patients, asymptomatic or symptomatic at baseline, had better Neuropsychiatric Inventory subscale scores than did patients receiving placebo. Behavioral improvement in patients symptomatic at baseline ranged from 29% to 48%. Changes were evident in patients receiving 16 or 24 mg/day of galantamine. High-dose galantamine was associated with a significant reduction in caregiver distress. Galantamine therapy was associated with reduced emergence of behavioral disturbances and improvement in existing behavioral problems in patients with mild to moderate Alzheimer's disease, with a concomitant reduction in reported caregiver distress.
- 1 March 2004
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 161 (3) , 532-538
Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer’s Disease
Alzheimer's disease pathology includes both histologic changes and neurotransmitter deficits. The cholinergic deficit contributes to both cognitive and behavioral disturbances, and cholinesterase inhibitors may improve behavior in Alzheimer's disease patients. This analysis was conducted to assess the impact of galantamine, a cholinesterase inhibitor with nicotinic-receptor-modulating properties, on the pattern and evolution of behavioral disturbances in patients with Alzheimer's disease and on caregiver distress related to patients' behavior. Data from 978 patients with mild to moderate Alzheimer's disease who were randomly assigned to placebo or galantamine (8, 16, or 24 mg/day) were analyzed. Behavioral changes were assessed with the Neuropsychiatric Inventory, and alterations in caregiver distress were measured by the Neuropsychiatric Inventory distress scale. Data collected at baseline and 12 and 21 weeks postbaseline were analyzed. Neuropsychiatric Inventory scores worsened with placebo, whereas patients treated with 16 or 24 mg/day of galantamine had no change in total Neuropsychiatric Inventory scores. Treated patients, asymptomatic or symptomatic at baseline, had better Neuropsychiatric Inventory subscale scores than did patients receiving placebo. Behavioral improvement in patients symptomatic at baseline ranged from 29% to 48%. Changes were evident in patients receiving 16 or 24 mg/day of galantamine. High-dose galantamine was associated with a significant reduction in caregiver distress. Galantamine therapy was associated with reduced emergence of behavioral disturbances and improvement in existing behavioral problems in patients with mild to moderate Alzheimer's disease, with a concomitant reduction in reported caregiver distress.
- 1 January 2004
- Published by Wiley in Archives of Pathology & Laboratory Medicine
- Vol. 128 (1) , 32-8
Comorbidity in dementia: an autopsy study.
There is a paucity of accurate postmortem data pertinent to comorbid medical conditions in patients with dementia, including Alzheimer disease. The purposes of this study were (a) to examine general autopsy findings in patients with a dementia syndrome and (b) to establish patterns of central nervous system comorbidity in these patients. Review of autopsy reports and selected case material from 202 demented patients who had "brain-only" autopsies during a 17-year period (1984-2000) and from 52 demented patients who had general autopsies during a 6-year period (1995-2000). Large academic medical center performing approximately 200 autopsies per year. Among the 52 patients who underwent complete autopsy, the most common cause of death was bronchopneumonia, which was found in 24 cases (46.1%). Other respiratory problems included emphysema, found in 19 (36.5%) of 52 patients, and pulmonary thromboembolism, found in 9 (17.3%) of 52 patients. In 6 cases, pulmonary thromboembolism was the proximate cause of death. Twenty-one (40.3%) of the 52 patients had evidence of a myocardial infarct (varying ages) and 38 (73.1%) had atherosclerotic cardiovascular disease, 27 of a moderate to severe degree. Four clinically unsuspected malignancies were found: 1 each of glioblastoma multiforme, diffusely infiltrative central nervous system lymphoma, pancreatic adenocarcinoma, and adenocarcinoma of the lung. One patient with frontotemporal dementia and amyotrophic lateral sclerosis died of severe meningoencephalitis/ventriculitis, probably secondary to seeding of the central nervous system by an infected cardiac valve. Of the 202 demented patients who underwent brain-only autopsies, the following types of dementia were found: 129 (63.8%) cases showed changes of severe Alzheimer disease, 21 (10.4%) showed combined neuropathologic abnormalities (Alzheimer disease plus another type of lesion, such as significant ischemic infarcts or diffuse Lewy body disease), 12 (5.9%) cases of relatively pure ischemic vascular dementia, 13 (6.4%) cases of diffuse Lewy body disease, and 8 (4.0%) cases of frontotemporal dementia. The remaining 19 (9.4%) patients showed miscellaneous neuropathologic diagnoses, including normal pressure hydrocephalus and progressive supranuclear palsy. Among the demented patients, 92 (45.5%) had cerebral atherosclerosis, which was moderate to severe in 65 patients (32.2%). Some of the conditions found at autopsy, had they been known antemortem, would likely have affected clinical management of the patients. Autopsy findings may be used as a quality-of-care measure in patients who have been hospitalized in chronic care facilities for a neurodegenerative disorder.
- 1 January 2004
- Published by Wiley in Archives of Pathology & Laboratory Medicine
- Vol. 128 (1) , 32-8
Comorbidity in dementia: an autopsy study.
There is a paucity of accurate postmortem data pertinent to comorbid medical conditions in patients with dementia, including Alzheimer disease. The purposes of this study were (a) to examine general autopsy findings in patients with a dementia syndrome and (b) to establish patterns of central nervous system comorbidity in these patients. Review of autopsy reports and selected case material from 202 demented patients who had "brain-only" autopsies during a 17-year period (1984-2000) and from 52 demented patients who had general autopsies during a 6-year period (1995-2000). Large academic medical center performing approximately 200 autopsies per year. Among the 52 patients who underwent complete autopsy, the most common cause of death was bronchopneumonia, which was found in 24 cases (46.1%). Other respiratory problems included emphysema, found in 19 (36.5%) of 52 patients, and pulmonary thromboembolism, found in 9 (17.3%) of 52 patients. In 6 cases, pulmonary thromboembolism was the proximate cause of death. Twenty-one (40.3%) of the 52 patients had evidence of a myocardial infarct (varying ages) and 38 (73.1%) had atherosclerotic cardiovascular disease, 27 of a moderate to severe degree. Four clinically unsuspected malignancies were found: 1 each of glioblastoma multiforme, diffusely infiltrative central nervous system lymphoma, pancreatic adenocarcinoma, and adenocarcinoma of the lung. One patient with frontotemporal dementia and amyotrophic lateral sclerosis died of severe meningoencephalitis/ventriculitis, probably secondary to seeding of the central nervous system by an infected cardiac valve. Of the 202 demented patients who underwent brain-only autopsies, the following types of dementia were found: 129 (63.8%) cases showed changes of severe Alzheimer disease, 21 (10.4%) showed combined neuropathologic abnormalities (Alzheimer disease plus another type of lesion, such as significant ischemic infarcts or diffuse Lewy body disease), 12 (5.9%) cases of relatively pure ischemic vascular dementia, 13 (6.4%) cases of diffuse Lewy body disease, and 8 (4.0%) cases of frontotemporal dementia. The remaining 19 (9.4%) patients showed miscellaneous neuropathologic diagnoses, including normal pressure hydrocephalus and progressive supranuclear palsy. Among the demented patients, 92 (45.5%) had cerebral atherosclerosis, which was moderate to severe in 65 patients (32.2%). Some of the conditions found at autopsy, had they been known antemortem, would likely have affected clinical management of the patients. Autopsy findings may be used as a quality-of-care measure in patients who have been hospitalized in chronic care facilities for a neurodegenerative disorder.
- 4 March 2003
- Vol. 11 (2) , 131-45
Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.
Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with Alzheimer disease (AD) and are the only class of drugs approved by the Food and Drug Administration (FDA) for treatment of this condition. This review provides evidenced-based recommendations for use of ChE-Is in clinical practice. The author searched computerized literature databases of the approved ChE-Is widely used in clinical practice (donepezil, rivastigmine, and galantamine), and extended the review with bibliographies from identified articles and package inserts of information reviewed by the FDA. Double-blind, placebo-controlled trials providing Class I evidence were used as data sources whenever possible. Articles with Class II and Class III data were used when Class I data were unavailable. In general, ChE-Is exert modest reproducible effects in patients with mild-to-moderate AD. Drug-placebo differences are evident on global and cognitive measures. Secondary outcomes, including measures of activities of daily living and behavior, also typically demonstrate drug-placebo differences in favor of the active agent. Head-to-head trials of ChE-Is are limited; existing trials suggest no major differences in efficacy. Observations from clinical trials imply that early initiation of therapy is associated with greater long-term benefits. Clinical trials with withdrawal periods indicate that withdrawal and re-initiation of treatment may result in loss of benefit. Open-label extensions of double-blind trials show that differences in level of functioning between treated populations and extrapolated for untreated populations continue for several years. Side effects of ChE-Is include nausea, vomiting, diarrhea, and anorexia, and are more frequent during dose escalation than maintenance therapy. Clinical-trial populations differ substantially from unselected populations of AD patients, and these selection biases demand that efficacy data from clinical trials be generalized with caution.
- 4 March 2003
- Vol. 11 (2) , 131-45
Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.
Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with Alzheimer disease (AD) and are the only class of drugs approved by the Food and Drug Administration (FDA) for treatment of this condition. This review provides evidenced-based recommendations for use of ChE-Is in clinical practice. The author searched computerized literature databases of the approved ChE-Is widely used in clinical practice (donepezil, rivastigmine, and galantamine), and extended the review with bibliographies from identified articles and package inserts of information reviewed by the FDA. Double-blind, placebo-controlled trials providing Class I evidence were used as data sources whenever possible. Articles with Class II and Class III data were used when Class I data were unavailable. In general, ChE-Is exert modest reproducible effects in patients with mild-to-moderate AD. Drug-placebo differences are evident on global and cognitive measures. Secondary outcomes, including measures of activities of daily living and behavior, also typically demonstrate drug-placebo differences in favor of the active agent. Head-to-head trials of ChE-Is are limited; existing trials suggest no major differences in efficacy. Observations from clinical trials imply that early initiation of therapy is associated with greater long-term benefits. Clinical trials with withdrawal periods indicate that withdrawal and re-initiation of treatment may result in loss of benefit. Open-label extensions of double-blind trials show that differences in level of functioning between treated populations and extrapolated for untreated populations continue for several years. Side effects of ChE-Is include nausea, vomiting, diarrhea, and anorexia, and are more frequent during dose escalation than maintenance therapy. Clinical-trial populations differ substantially from unselected populations of AD patients, and these selection biases demand that efficacy data from clinical trials be generalized with caution.